2'-phenyl-5-(4-methylpiperazinyl)-2,5'-bi-1H-benzimidazole | 23623-08-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 2'-phenyl-5-(4-methylpiperazinyl)-2,5'-bi-1H-benzimidazole
• 英文别名: 5-(4-methyl-piperazin-1-yl)-2'-phenyl-1H,1'H-[2,5']bibenzoimidazolyl；6-(4-methylpiperazin-1-yl)-2-(2-phenyl-3H-benzimidazol-5-yl)-1H-benzimidazole
• CAS: 23623-08-7
• 化学式: C₂₅H₂₄N₆
• 分子量: 408.506
• InChiKey: SOUKAPYFWOYMNH-UHFFFAOYSA-N

物化性质

• 沸点：
  700.4±70.0 °C(Predicted)
• 密度：
  1.298±0.06 g/cm3(Predicted)
• 溶解度：
  25℃：DMSO或水 避光

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  31
• 可旋转键数：
  3
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  63.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  3,4-二氨基苯甲腈 在 aluminum nickel 甲酸 作用下， 以 硝基苯 为溶剂， 反应 6.0h， 生成 2'-phenyl-5-(4-methylpiperazinyl)-2,5'-bi-1H-benzimidazole
  参考文献：
  名称：

  Substituted 2,5‘-Bi-1H-benzimidazoles:  Topoisomerase I Inhibition and Cytotoxicity

  摘要：

  Several 2'-aryl-5-substituted-2,5'-bi-1H-benzimidazole derivatives were synthesized and evaluated as topoisomerase I poisons and for their cytotoxicity toward the human lymphoblast cell line RPMI 8402. This study focused on 18 2,5'-bi-1H-benzimidazole derivatives which contained either a 5-cyano, a 5-(aminocarbonyl), or a 5-(4-methylpiperazinyl) group. Among these bibenximidazoles, the pharmacological activity of 2'-phenyl derivatives and the influence of the different positional isomers of either a 2'-tolyl group or a 2'-naphthyl moiety on cytotoxicity and topoisomerase I inhibitory activity were determined.

  DOI：

  10.1021/jm950412w

文献信息

• [EN] HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES<br/>[FR] COMPOSÉS À PETITES MOLÉCULES MIMÉTIQUES DES FACTEURS DE CROISSANCE HÉMATOPOÏÉTIQUE ET LEURS UTILISATIONS
  申请人：LIGAND PHARM INC

  公开号：WO2011046954A1

  公开（公告）日：2011-04-21

  The present embodiments relate to compounds with physiological effects, such as the activation of hematopoietic growth factor receptors. The present embodiments also relate to use of the compounds to treat a variety of conditions, diseases and ailments such as hematopoietic conditions and disorders.

  目前的实施例涉及具有生理效应的化合物，例如激活造血生长因子受体。目前的实施例还涉及利用这些化合物来治疗各种疾病、疾病和疾患，如造血状况和疾病。
• HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES
  申请人：Zhi Lin

  公开号：US20120295904A1

  公开（公告）日：2012-11-22

  The present embodiments relate to compounds with physiological effects, such as the activation of hematopoietic growth factor receptors. The present embodiments also relate to use of the compounds to treat a variety of conditions, diseases and ailments such as hematopoietic conditions and disorders.

  本实施例涉及具有生理效应的化合物，例如激活造血生长因子受体。本实施例还涉及使用这些化合物来治疗各种状况、疾病和疾病，例如造血系统状况和疾病。
• USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS
  申请人：Bissonnette Reid P.

  公开号：US20140243324A1

  公开（公告）日：2014-08-28

  The present invention relates to uses of small molecule mimetics of hematopoietic growth factors. In particular the present invention relates to uses of small molecule mimetics of erythropoietin.

  本发明涉及使用小分子模拟血液生成生长因子的用途。特别是本发明涉及使用小分子模拟红细胞生成素的用途。
• Methods to mobilize tissue resident cells for adoptive t cell therapy
  申请人：Emory University

  公开号：US11213546B2

  公开（公告）日：2022-01-04

  The present disclosure includes compositions, methods, and uses for a subset of T cells, SP T (TSP) cells, which display a quiescent (G0) phenotype. Aspects of the disclosure include methods for obtaining and mobilizing TSP cells in a subject. Other aspects include methods of adoptive cell transfer in a subject utilizing TSP cells.

  本公开包括显示静止（G0）表型的 T 细胞亚群 SP T（TSP）细胞的组合物、方法和用途。本公开的各个方面包括在受试者体内获得和动员 TSP 细胞的方法。其他方面包括利用 TSP 细胞在受试者体内进行收养性细胞转移的方法。
• Methods to Mobilize Tissue Resident Cells for Adoptive T Cell Therapy
  申请人：YALE UNIVERSITY

  公开号：US20190070221A1

  公开（公告）日：2019-03-07

  The present disclosure includes compositions, methods, and uses for a subset of T cells, SP T (T SP ) cells, which display a quiescent (G0) phenotype. Aspects of the disclosure include methods for obtaining and mobilizing T SP cells in a subject. Other aspects include methods of adoptive cell transfer in a subject utilizing T SP cells.